ArticleThe Journal of clinical investigation2026
In vivo CRISPR screens identify CBX4 as an epigenetic regulator for cancer immunotherapy.
Zhibo Ma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it